Best practices for ensuring cell and gene therapy supply chain scalability 2022

A collaborative approach to cell & gene therapy supply chain management

Cell & Gene Therapy Insights 2022; 8(3), 435 – 441

DOI: 10.18609/cgti.2022.064

Published: 24 April 2022
Anthony Johnson

David McCall, Commissioning Editor, Cell & Gene Therapy Insights, talks to Anthony Johnson, Head of Supply Chain & Warehouse, Cell and Gene Therapy Catapult

ANTHONY JOHNSON is an Operations leader with experience in manufacturing, facilities, and supply chain management, with over 15 years experience in the pharmaceutical sector. Since 2021 Tony has worked for Catapult Cell & Gene Therapy as Head of Supply Chain & Warehouse. Prior to this he worked in Operations and Manufacturing leadership roles, for GSK, Bio Product laboratories and Catalent. He was responsible for leading teams in manufacturing of micronised respiratory and ODS API’s, IGG and CF blood products and modified release technologies.